Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

EKF Diagnostics Celebrates Success at MEDICA 2012

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
Attendance statistics highlight interest in new point-of-care tools.

EKF Diagnostics’ success at MEDICA 2012 has been highlighted by a list of impressive statistics. The worldwide manufacturer of point-of-care (POC) diagnostic tools attracted numerous visitors to find out more about the 10 key products displayed on its 100m2 stand.  Generating the greatest interest was the European launch of two new POC products: the Quo-Lab glycated haemoglobin (HbA1c) analyser for the affordable management of diabetes; and the STAT-SiteTM M ßHB strip-based analyser, for highly accurate near patient testing of ketosis.

Over 200 product demos and 66 customer meetings were given to delegates to demonstrate the qualities of EKF Diagnostics’ newest POC solutions. The semi-automated, CE marked Quo-Lab analyser monitors HbA1c, which is increasingly used in the detection and management of diabetes, and provides a highly accurate, affordable and easy-to-use technology for GP surgeries, diabetes clinics and laboratories. The STAT-SiteTM M ßHB has been developed for the measurement of ß-Hydroxybutyrate (ßHB), the main ketone produced during ketosis, and provides a quantitative and accurate assessment of patients displaying symptoms of ketosis. This makes ketosis testing easier and more affordable in POC settings.

Nine free mini-seminars, attended by 121 delegates, outlined the benefits of using Quo-Lab and STAT SiteTM M ßHB, alongside the Lactate Scout+ for lactate measurement in obstetrics, and the Hemo-Control Manager for haemoglobin analysis and data management. A range of clinical chemistry reagents were also presented by EKF product specialists, including the ß-Hydroxybutyrate (ßHB) LiquiColor® Reagent System developed by EKF subsidiary, Stanbio Laboratory, which is relied on by 13 of the USA’s top 25 diabetes and endocrinology hospitals for its rapid and reliable results.

According to Julian Baines, Group CEO, “The launch of our two new POC products for diabetes and ketosis testing at Medica this year was a tremendous success, which was reflected in the interest shown by the large number of attendees visiting our stand. We were delighted with the response to our seminar series. The seminars provided a great way to update customers Quo-Lab and STAT-Site M BHB and also brush up their knowledge on established EKF products.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Selah Genomics and DiaSpect Medical
Combined with the recent acquisition of Seperation Technology the purchases strengthen EKF’s product and services offering.
Tuesday, April 22, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos